Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Head & Neck 2Gynecologic 2Dermatologic 2Breast 2Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Metformin × Dermatologic × Clear all
NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

University of Louisville

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT01638676 2021-10-29

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

University of Louisville

Phase 1/2 Recruiting
55 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡